Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA
Update: 2025-10-23
Description
Featuring an interview with Dr Eunice S Wang, including the following topics:
- Hypomethylating agent/venetoclax combinations for the treatment of acute myeloid leukemia (AML); integration in community practice (0:00 )
- All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed AML not eligible for intensive induction chemotherapy (9:39 )
- Efficacy of targeted therapy options for AML; potential role of MRD (minimal residual disease) assays in monitoring treatment response (13:07 )
- Treatment approach for patients with FLT3-mutant AML; mutation profiles and predicting response to quizartinib (20:14 )
- Targeting the differentiation of AML tumor cells with IDH and menin inhibitors; associated differentiation syndrome (29:24 )
- Efficacy and tolerability of the IDH inhibitors ivosidenib and olutasidenib (36:54 )
- Key clinical data with approved and investigational menin inhibitors for AML; current and potential integration of menin inhibitors in the AML treatment algorithm (42:30 )
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
